Sermorelin is a synthetic 29-aa GHRH(1-29) peptide (CAS 86168-78-7). Formula/mass anchors and lot COA purity panels. Research use only.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to GHRH(1-29), the shortest fully active fragment of human growth hormone-releasing hormone. It is a discrete research material with its own CAS, formula, molar mass, and lot documentation — not a catalogue nickname for every “GHRH” listing, and not a synonym for full-length GHRH, unrelated GH-axis research SKUs, or consumer therapy products.
If you found “sermorelin,” “sermorelin research peptide,” “ghrh 1-29,” “sermorelin coa,” “sermorelin purity,” or “sermorelin third party tested” in a listing, the useful questions are which registry fields the seller claims, whether the certificate matches those anchors, and how the vial lot is documented. Aliases vary; registry fields and certificates do not.
This page covers Peptide Foundry’s published identity anchors, the purity panels a research buyer should demand, a worked third-party lot for the live 10 mg option, and short tool-compound naming literacy — then soft-handoffs to the Sermorelin research product page. Research use only.
Key points
- Sermorelin = synthetic 29-amino-acid peptide corresponding to GHRH(1-29) (shortest fully active fragment of human GHRH); supplied as lyophilized research material. Listing aliases GHRH 1-29 / GRF 1-29 = naming literacy only — not a therapy claim.
- Peptide Foundry catalog anchors (live PDP): CAS 86168-78-7, formula C149H246N44O42S, molar mass 3357.9 g/mol — match certificate fields to these claims. A letter sequence is not listed on the live PDP and is not invented here.
- SKU
PF-SERMORELIN; live size option 10 mg lyophilized — match each vial to its own lot certificate (current worked example = FO339 / ILS).- Demand a lot-matched COA: HPLC purity with method/wavelength when stated, identity method, named laboratory, and preferably independent portal verify; “third-party tested” or “high purity” without lot + named lab is unfinished.
- Research use only — not for human or veterinary use; not a growth hormone therapy, anti-aging, body-composition, wellness, or consumer secretagogue product.
What is Sermorelin?
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). Residue count is twenty-nine. The research material on this page is that defined fragment class with the published registry anchors below — not a crude tissue extract and not a brand stack.
A short historical note anchors naming only. Published work associated with 1980s GHRH structure research — including the 1982 isolation and characterization of growth hormone-releasing hormone by Roger Guillemin’s team at the Salk Institute — established that the N-terminal 29 residues retained in vitro receptor-binding activity comparable to the full-length 44-amino-acid peptide. That is origin and naming / tool-compound history — not a catalogue mechanism claim, not registry proof, and not a reason to treat every “GHRH” nickname as interchangeable or as a consumer therapy product.
Physical form on research listings is lyophilized solid. Peptide Foundry’s current catalog documents describe lyophilized powder under SKU PF-SERMORELIN at a 10 mg size option. Appearance is a handling observation — not a purity proof and not a substitute for HPLC or identity data on a certificate.
Market aliases include Sermorelin, GHRH 1-29, GHRH(1-29), and GRF 1-29. Aliases help search and inventory. They are not identity proof until you have CAS, formula, molar mass, GHRH(1-29) framing, and a lot-matched certificate — and they are not a drug- or therapy-as-benefit claim. The live Peptide Foundry PDP does not publish a one-letter sequence or an alternate acetate CAS; this page follows that publication set and does not invent either.
Chemical identity anchors
Peptide Foundry publishes a fixed identity set for single-vial Sermorelin. The values below match the live catalog chemistry table at the time of writing. Confirm against the current product page if a lot or chemistry block rotates after publish.
Naming and class
Class: synthetic 29-amino-acid peptide corresponding to GHRH(1-29); GHRH-receptor research tool compound (literature class). Listing aliases: GHRH 1-29 / GRF 1-29 (naming only — not therapy-as-benefit). SKU PF-SERMORELIN; size option on the live listing at publish time: 10 mg lyophilized.
CAS, formula, and molar mass
| Field | Peptide Foundry catalog (live /product/sermorelin/) |
|---|---|
| CAS | 86168-78-7 |
| Formula | C149H246N44O42S |
| Molar mass | 3357.9 g/mol |
| Length / class | Synthetic 29-aa peptide corresponding to GHRH(1-29) |
| Listing aliases | GHRH 1-29 / GRF 1-29 (naming only — not therapy-as-benefit) |
| SKU | PF-SERMORELIN |
| Form | Lyophilized |
| Size (live option) | 10 mg |
Market pages sometimes round mass differently, recycle CAS strings across unrelated GHRH nicknames, or publish an alternate acetate CAS not shown on Peptide Foundry’s live chemistry table. The practical rule is: match the vendor’s stated CAS + formula + molar mass + GHRH(1-29) framing to the lot COA, then prefer orthogonal identity (MS / HPLC-RTM) over the nickname alone.
What a Sermorelin COA should show
A certificate of analysis is stronger when it is lot-specific, names the laboratory, states methods, and can be checked outside the supplier’s own site. For the full verification workflow — batch match, named lab, HPLC versus identity, biosafety panels, portal codes — see How to read a research-peptide COA.
Minimum research COA fields
- A lot / batch ID that matches the vial character for character
- Test or report date(s) and a named laboratory
- HPLC purity with method (and wavelength when stated — for example 214 nm)
- An identity method (MS and/or HPLC-RTM)
- Product name / composition consistent with the label and the vendor’s published anchors
“Third-party tested,” “high purity Sermorelin,” or “99%+” without a named lab and a lot number is an unfinished claim. A pretty PDF that cannot be tied to the vial in hand is documentation theater.
Stronger panels (when claimed)
When a full QC panel is present — the pattern on current Peptide Foundry ILS-tested lots — read these as separate analytical results:
- Mass-spectrometry or HPLC-RTM identity confirmation
- Net peptide content versus labeled mass when reported
- Heavy metals by ICP-MS against stated limits
- Sterility / no growth
- Endotoxin (for example USP <85> / LAL)
- Illicit-substance screen (for example fentanyl — not detected)
These describe composition and contamination panels for research documentation. They are not a safety-for-human-use claim, and they do not replace identity or purity.
Worked example — lot FO339 (10 mg)
As published on the current Peptide Foundry Sermorelin listing at the time of writing for the 10 mg option:
| Field | Value |
|---|---|
| Lot | FO339 |
| Size | 10 mg |
| Laboratory | ILS Laboratories |
| Received | 07/16/2026 |
| Tested | 07/19/2026 |
| Purity | 99.28% (HPLC @ 214 nm) |
| Net peptide content | 10.61 mg |
| Identity | HPLC-RTM — Pass |
| Fentanyl screen | Not Detected |
| Heavy metals | Pass |
| Sterility | No Growth |
| Endotoxin | NMT 0.05 EU/mL |
| Access code | 2TVQ2GYZ |
Cite those figures as Peptide Foundry–published transparency for this lot — not a universal industry floor. Re-verify against the live product panel if the lot rotates after publish.
Three steps that travel with any lot, not just FO339:
- Match the lot number on the vial to the lot on the certificate.
- Confirm CAS, formula, and labeled mass against the certificate and the product label.
- Verify the access code on the issuing laboratory’s own portal (ILS for FO339: access code 2TVQ2GYZ) — not only by opening a PDF hosted by the supplier.
Portable vendor criteria beyond a single SKU: USA research-peptide vendor criteria.
Related research peers (soft handoffs)
Research catalogues sometimes co-browse GHRH-axis materials beside Sermorelin listings. Co-browsing is inventory adjacency — not a synonym set and not a protocol for combining materials.
- TH9507 / tesamorelin research identity — live GHRH-axis research identity sibling; match each vial to its own CAS, formula, and lot certificate.
- CJC-1295 + Ipamorelin research identity — live GHRH / GHRP catalog sibling; chemical/class literacy only, never a stack recommendation.
- How to read a research-peptide COA and USA research-peptide vendor criteria — same trust workflow.
- Lyophilized peptide reconstitution — general lab diluent literacy without Sermorelin schedules.
Match each vial to its own registry fields and lot certificate. Shared catalogue adjacency is literacy — not a stack recommendation.
Tool-compound / naming literacy (preclinical framing only)
Mechanism language is useful here only as classification of experimental systems in published literature. It does not establish catalogue-product outcomes in people, and it does not convert a citation into a certificate. Do not treat paper titles as product-use claims.
| Literature / naming class (examples) | Acceptable framing on this page | Not used as product framing |
|---|---|---|
| Synthetic GHRH(1-29) / 29-aa shortest fully active fragment | Listing name Sermorelin refers to a published synthetic 29-aa peptide corresponding to GHRH(1-29) used as a research tool compound | Growth hormone therapy peptide, anti-aging product, or secretagogue consumer product |
| GHRH receptor binding in preclinical / in vitro models | Examined in preclinical publications exploring GHRH-receptor binding / GHRH-axis signaling in cell-culture or preclinical models | GH release outcomes for people; anti-aging, body-composition, muscle, or recovery product claims |
| GHRH 1-29 / GRF 1-29 listing aliases | GHRH 1-29 / GRF 1-29 appear as listing aliases for the same research material — match CAS, formula, and lot COA | Drug, compounding-pharmacy, or prescription framing as product benefit |
Therapeutic-adjacent titles that appear in wider SERPs sit outside the scope of this RUO identity page and are not summarized as product use. Keep tool-compound class attached to the source paper and the experimental system. Identity remains an analytical question answered by CAS, formula, GHRH(1-29) framing, and the lot COA.
Storage and lab handling (lyophilized)
Standard laboratory practice for lyophilized synthetic peptides applies:
- Storage. Sealed vials at −20°C, protected from light and moisture. Lyophilized material is substantially more stable than solution.
- Temperature excursions. Brief ambient exposure in transit is normal for lyophilized material. Return vials to −20°C on arrival.
- Freeze–thaw. Minimize repeated freeze–thaw.
- Traceability. Keep the lot number with the material — lot number ties a vial back to its certificate.
Assay-specific handling follows your institution’s SOPs. This page does not publish personal reconstitution schedules, dosing charts, or solution-use protocols for Sermorelin. General lyophilized-material diluent literacy (without compound-specific schedules) lives at Lyophilized peptide reconstitution.
Common questions
What is Sermorelin’s CAS, formula, and mass?
CAS 86168-78-7; formula C149H246N44O42S; molar mass 3357.9 g/mol; synthetic 29-amino-acid peptide corresponding to GHRH(1-29). Peptide Foundry catalogs the material as SKU PF-SERMORELIN (10 mg lyophilized option at publish time). The live PDP does not publish a letter amino-acid sequence or an alternate acetate CAS; prefer registry fields over listing nicknames.
Is Sermorelin the same as GHRH 1-29 / GRF 1-29?
Those strings are the same listing/alias family for this GHRH(1-29) fragment class when CAS, formula, molar mass, and the lot certificate agree. Styling is not a second compound. On this RUO page, GHRH 1-29 / GRF 1-29 are naming literacy only — not a therapy claim. Match registry fields and the vial lot — do not treat an alternate hyphenation as identity proof by itself.
What makes a Sermorelin COA usable — and what does “third-party tested” require?
Lot match to the vial, a named laboratory, HPLC purity with method/wavelength when stated, an identity method (MS and/or HPLC-RTM), and preferably an independent portal verify path. Stronger documentation adds net peptide content, heavy metals, sterility, endotoxin, and illicit screens when claimed. Worked FO339 figures above — ILS Laboratories, HPLC 99.28% @ 214 nm, HPLC-RTM pass, net 10.61 mg, access code 2TVQ2GYZ — are an example of that pattern on Peptide Foundry’s live listing. Workflow detail: How to read a research-peptide COA.
Is this for growth hormone therapy, anti-aging, body composition, secretagogue use, or human use?
No. Peptide Foundry supplies Sermorelin strictly for laboratory and research use by qualified researchers. Mentions of GHRH-receptor binding in published preclinical literature are tool-compound / literature-class context only — not product benefits and not human therapy. Listing aliases such as GHRH 1-29 are naming literacy only, not a drug- or therapy-as-benefit claim. This page does not describe consumer finished goods, personal-use schedules, administration protocols, or stack recommendations. Sermorelin here is not a drug, supplement, wellness product, consumer finished good, or veterinary product, and not for use in people or animals.
For the current lot certificate and product specifications, see the Sermorelin research product page. Related library reading: How to read a research-peptide COA, USA research-peptide vendor criteria, Lyophilized peptide reconstitution, TH9507 research identity, and CJC-1295 + Ipamorelin research identity.
Research use only. Nothing on this page describes or implies use in humans or animals. Tool-compound mentions of GHRH-receptor binding or GHRH-axis signaling refer only to preclinical and in-vitro literature contexts and are not product outcomes.
